'Folfox 4' diaporamas de présentation

Treating Advanced Colorectal Cancer: 15 minutes, 13 abstracts

Treating Advanced Colorectal Cancer: 15 minutes, 13 abstracts. Richard M Goldberg MD Professor and Chief of Heme/Onc Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill. Topics: Chemotherapy N = 2241. First-line chemotherapy comparisons

825 views • 71 slides

Targeted Therapies in Metastatic Colorectal Cancer: An Update

Targeted Therapies in Metastatic Colorectal Cancer: An Update. ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update. Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab use beyond first progression linked to improvement in survival outcomes

651 views • 40 slides

Rationale for the NO16967 study

Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), folinic acid (FA), and oxaliplatin (FOLFOX-4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC).

359 views • 22 slides

Abstract ? 4532

DEFINITIVE CHEMORADIOTHERAPY (CRT) WITH FOLFOX 4 OR 5FU-CISPLATIN AS FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH INOPERABLE ESOPHAGEAL CANCER (IEC) : FINAL RESULTS OF A RANDOMIZED PHASE II STUDY.

333 views • 21 slides

Reviewer: Dr Scott Berry Date posted: June 21, 2007

CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC) Authors: Cassidy, Saltz et al. Reviewer: Dr Scott Berry Date posted: June 21, 2007. Background.

260 views • 12 slides

*Carsten Bokemeyer , Elzbieta Staroslawska, Marek Nowacki, Irina Mitashok, Elena Kuznetsova,

183 views • 8 slides